We are happy to announce our selection for ScaleReady's prestigious G-Rex® Grant Program. This allows us to further validate and optimize our technology across all G-Rex® models, with a focus on developing robust, scalable, and regulatory-compliant processes. The grant will be used to support a series of experiments aimed at optimizing T-lymphocyte activation and expansion using various media, cytokines, and culture configurations. Data generated from this work will contribute to the process improvements and provide a foundation for potential manufacturing changes or supplier switches.
Our CEO, Dr. Luka Fajs, commented:
"We are excited to partner with ScaleReady through the G-Rex® Grant Program. The program provides us with crucial resources and expert guidance, but also reinforces our shared mission to simplify and improve the manufacturing of cell therapies. Our goal is to develop and share optimized protocols that can streamline T-cell manufacturing for the entire field."
Josh Ludwig, Global Commercial Director of ScaleReady, commented:
"We are hopeful that Bio-ReCell will continue the great progress we have observed in developing this simplified activation reagent. This aligns with ScaleReady's ongoing efforts to streamline CGT production in order to broaden patient access."
About ScaleReady
ScaleReady is a joint venture between Bio-Techne, Fresenius Kabi, and Wilson Wolf, combining proven technologies to deliver simple, scalable, and cost-effective manufacturing solutions for cell and gene therapy, with a focus on accelerating the transition from research to clinical and commercial production. Backed by deep industry expertise and global reach, ScaleReady empowers cell therapy developers to bring life-saving treatments to patients faster.
For more information visit: www.scaleready.com